Document is current
Any future updates will be listed below
-
Authors
Tommola, Minna http://orcid.org/0000-0003-4201-389X
Won, Ha-Kyeong
Ilmarinen, Pinja
Jung, Heewon
Tuomisto, Leena E.
Lehtimäki, Lauri
Niemelä, Onni
Kim, Tae-Bum
Kankaanranta, Hannu
-
Funding
Funding for this research was provided by:
Suomen Tuberkuloosin Vastustamisyhdistyksen Säätiö
Tampereen Tuberkuloosisäätiö
Hengityssairauksien Tutkimussäätiö
Orionin Tutkimussäätiö
Comptetitive state research financing of the expert responsibility area of Tampere University Hospital
Medical Research fund of Seinäjoki Central Hospital
Korea Health Technology R&D Project through the Korea Helalth Industry Development Institute
- License Information
-
More Information
Article History
Received: 14 November 2019
Accepted: 6 July 2020
First Online: 13 July 2020
Ethics approval and consent to participate
: All enrolled participants in COREA cohort and in SAAS cohort signed informed consent. The protocol and design of COREA cohort were approved by the institutional review board of each center. The study protocol of SAAS was approved by the Ethics committee of Tampere University Hospital, Tampere, Finland (R12122).
: Dr. Tommola reports personal fees from Astra Zeneca, personal fees from Boehringer ingelheim, personal fees from Pfizer, grants from Orion research foundation, personal fees from Chiesi, outside the submitted work. Dr. Won has nothing to disclose. Dr. Ilmarinen reports grants and personal fees from Astra Zeneca, personal fees from Mundipharma, personal fees from GlaxoSmithKline, personal fees from Orion, personal fees from Novartis, outside the submitted work. Dr. Jung has nothing to disclose. Dr. Tuomisto reports non-financial support from Chiesi, non-financial support from Boehringer-Ingelheim, personal fees from Astra Zeneca, non-financial support from Orion Pharma, non-financial support from TEVA, other from Novartis, outside the submitted work. Dr. Lehtimäki reports personal fees from ALK, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GSK, personal fees from Mundipharma, personal fees from Novartis, personal fees from OrionPharma, outside the submitted work. Dr. Niemelä has nothing to disclose. Dr. Kankaanranta reports grants, personal fees and non-financial support from AstraZeneca, personal fees from Chiesi Pharma AB, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Novartis, personal fees from Mundipharma, personal fees and non-financial support from Orion Pharma, personal fees from SanofiGenzyme, personal fees from GlaxoSmithKline, outside the submitted work. Dr. Kim has nothing to disclose.
